CIK 0000899923 · Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 870494517
- Phone
- 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- 4 Grant or award Director acquired 7,575 shares (grant or award)
- 4 Grant or award Director acquired 15,151 shares (grant or award)
- 4 Grant or award Director acquired 15,151 shares (grant or award)
- 4 Open-market sale Director sold 8,638 shares at $23.01 ($198,760)
- 4 Grant or award Director acquired 15,151 shares (grant or award)
- 4 Grant or award Director acquired 15,151 shares (grant or award)
- 4 Grant or award Director acquired 15,151 shares (grant or award)
- 4 Grant or award Director acquired 15,151 shares (grant or award)
- 8-K Event Executive or director change · Bylaws or fiscal year change · Shareholder vote results
- 144 Insider Sale of Securities
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Shares withheld for taxes Chief Commercial Officer gave up 703 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 638 shares (to pay taxes)
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Open-market sale Chief Operating Officer sold 6,433 shares at $23.48 ($151,047)
Page 17 of 104 · 2,077 filings